News from NORD

More Than 100 Patient Organizations Join NORD in Supporting the RARE Act


 

NORD has sent a letter to Congress, signed by more than 100 patient advocacy organizations, in support of the Rare disease Advancement, Research, and Education Act of 2018 (H.R.5115) or the “RARE Act of 2018.” Read NORD’s letter to see how this proposed legislation would help patients and families affected by rare diseases, medical researchers, and clinicians seeking to provide optimal care for their patients.

Recommended Reading

FDA advisory committee recommends volanesorsen for rare triglyceride disorder
MDedge Internal Medicine
Osteogenesis Imperfecta Foundation (OIF)
MDedge Internal Medicine
Malignant pleural mesothelioma guidelines often are ignored
MDedge Internal Medicine
Pemphigus remission rate tops 80% with rituximab
MDedge Internal Medicine
FDA approves rituximab for treating pemphigus vulgaris
MDedge Internal Medicine
FDA approves Epidiolex for Lennox-Gastaut syndrome and Dravet syndrome
MDedge Internal Medicine
Oral drug seen preventing angioedema attacks
MDedge Internal Medicine
Register Now for NORD’s Rare Impact Awards Celebration
MDedge Internal Medicine
2018 Marks 35th Anniversary of NORD and the Orphan Drug Act
MDedge Internal Medicine
RFPs Available for the Study of Three Rare Diseases
MDedge Internal Medicine